Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
  2. News
  3. prostate adenocarcinoma
Show results for
Products
Services
Applications
Companies
News
Refine by
Date

Prostate Adenocarcinoma Articles & Analysis

1 news found
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

(Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced results from its ongoing Phase 2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with ...

ByBioXcel Therapeutics, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you